In conclusion, our findings, that should be validated in a larger prospective trial, provide a framework for sustaining molecular-based patient-tailored treatments, employing RAD51 inhibitors as single agents or in combination with other therapies for cervical cancer. The gene discussed is RAD51; the disease is cervical carcinoma.